Report cover image

Recombinant Vector Vaccines Industry Research Report 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 124 Pages
SKU # APRC20543406

Description

Summary

According to APO Research, the global Recombinant Vector Vaccines market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Recombinant Vector Vaccines include SANOFI PASTEUR S.A., CNBG, SINOVAC BIOTECH, Zhifei, GSK, Hualan Bio, ChengDa Bio, NuoCheng Bio and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Vector Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Vector Vaccines.

The report will help the Recombinant Vector Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Recombinant Vector Vaccines market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Vector Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Recombinant Vector Vaccines Segment by Company
SANOFI PASTEUR S.A. CNBG SINOVAC BIOTECH Zhifei GSK Hualan Bio ChengDa Bio NuoCheng Bio Novartis Kangtai Changsheng LifeRecombinant Vector Vaccines Segment by Type
Varicella Influenza Hepatitis Pneumococcal Pertussis, Diphtheria, tetanus OthersRecombinant Vector Vaccines Segment by Application
For Adult For ChildRecombinant Vector Vaccines Segment by Region
North America United States Canada Europe Germany France U.K. Italy Netherlands Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia UAE

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vector Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vector Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vector Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Recombinant Vector Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Recombinant Vector Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Recombinant Vector Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

124 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Recombinant Vector Vaccines Market Size (2020-2031)
2.2.2 Global Recombinant Vector Vaccines Sales (2020-2031)
2.2.3 Global Recombinant Vector Vaccines Market Average Price (2020-2031)
2.3 Recombinant Vector Vaccines by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Varicella
2.3.3 Influenza
2.3.4 Hepatitis
2.3.5 Pneumococcal
2.3.6 Pertussis, Diphtheria, tetanus
2.3.7 Others
2.4 Recombinant Vector Vaccines by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 For Adult
2.4.3 For Child
3 Market Competitive Landscape by Manufacturers
3.1 Global Recombinant Vector Vaccines Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Recombinant Vector Vaccines Sales (k units) of Manufacturers (2020-2025)
3.3 Global Recombinant Vector Vaccines Revenue of Manufacturers (2020-2025)
3.4 Global Recombinant Vector Vaccines Average Price by Manufacturers (2020-2025)
3.5 Global Recombinant Vector Vaccines Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Recombinant Vector Vaccines, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Recombinant Vector Vaccines, Product Type & Application
3.8 Global Manufacturers of Recombinant Vector Vaccines, Established Date
3.9 Global Recombinant Vector Vaccines Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 SANOFI PASTEUR S.A.
4.1.1 SANOFI PASTEUR S.A. Company Information
4.1.2 SANOFI PASTEUR S.A. Business Overview
4.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio
4.1.5 SANOFI PASTEUR S.A. Recent Developments
4.2 CNBG
4.2.1 CNBG Company Information
4.2.2 CNBG Business Overview
4.2.3 CNBG Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.2.4 CNBG Recombinant Vector Vaccines Product Portfolio
4.2.5 CNBG Recent Developments
4.3 SINOVAC BIOTECH
4.3.1 SINOVAC BIOTECH Company Information
4.3.2 SINOVAC BIOTECH Business Overview
4.3.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.3.4 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio
4.3.5 SINOVAC BIOTECH Recent Developments
4.4 Zhifei
4.4.1 Zhifei Company Information
4.4.2 Zhifei Business Overview
4.4.3 Zhifei Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Zhifei Recombinant Vector Vaccines Product Portfolio
4.4.5 Zhifei Recent Developments
4.5 GSK
4.5.1 GSK Company Information
4.5.2 GSK Business Overview
4.5.3 GSK Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.5.4 GSK Recombinant Vector Vaccines Product Portfolio
4.5.5 GSK Recent Developments
4.6 Hualan Bio
4.6.1 Hualan Bio Company Information
4.6.2 Hualan Bio Business Overview
4.6.3 Hualan Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Hualan Bio Recombinant Vector Vaccines Product Portfolio
4.6.5 Hualan Bio Recent Developments
4.7 ChengDa Bio
4.7.1 ChengDa Bio Company Information
4.7.2 ChengDa Bio Business Overview
4.7.3 ChengDa Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.7.4 ChengDa Bio Recombinant Vector Vaccines Product Portfolio
4.7.5 ChengDa Bio Recent Developments
4.8 NuoCheng Bio
4.8.1 NuoCheng Bio Company Information
4.8.2 NuoCheng Bio Business Overview
4.8.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.8.4 NuoCheng Bio Recombinant Vector Vaccines Product Portfolio
4.8.5 NuoCheng Bio Recent Developments
4.9 Novartis
4.9.1 Novartis Company Information
4.9.2 Novartis Business Overview
4.9.3 Novartis Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Novartis Recombinant Vector Vaccines Product Portfolio
4.9.5 Novartis Recent Developments
4.10 Kangtai
4.10.1 Kangtai Company Information
4.10.2 Kangtai Business Overview
4.10.3 Kangtai Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Kangtai Recombinant Vector Vaccines Product Portfolio
4.10.5 Kangtai Recent Developments
4.11 Changsheng Life
4.11.1 Changsheng Life Company Information
4.11.2 Changsheng Life Business Overview
4.11.3 Changsheng Life Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Changsheng Life Recombinant Vector Vaccines Product Portfolio
4.11.5 Changsheng Life Recent Developments
5 Global Recombinant Vector Vaccines Market Scenario by Region
5.1 Global Recombinant Vector Vaccines Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Recombinant Vector Vaccines Sales by Region: 2020-2031
5.2.1 Global Recombinant Vector Vaccines Sales by Region: 2020-2025
5.2.2 Global Recombinant Vector Vaccines Sales by Region: 2026-2031
5.3 Global Recombinant Vector Vaccines Revenue by Region: 2020-2031
5.3.1 Global Recombinant Vector Vaccines Revenue by Region: 2020-2025
5.3.2 Global Recombinant Vector Vaccines Revenue by Region: 2026-2031
5.4 North America Recombinant Vector Vaccines Market Facts & Figures by Country
5.4.1 North America Recombinant Vector Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Recombinant Vector Vaccines Sales by Country (2020-2031)
5.4.3 North America Recombinant Vector Vaccines Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Recombinant Vector Vaccines Market Facts & Figures by Country
5.5.1 Europe Recombinant Vector Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Recombinant Vector Vaccines Sales by Country (2020-2031)
5.5.3 Europe Recombinant Vector Vaccines Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Recombinant Vector Vaccines Market Facts & Figures by Country
5.6.1 Asia Pacific Recombinant Vector Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Recombinant Vector Vaccines Sales by Country (2020-2031)
5.6.3 Asia Pacific Recombinant Vector Vaccines Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Recombinant Vector Vaccines Market Facts & Figures by Country
5.7.1 South America Recombinant Vector Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Recombinant Vector Vaccines Sales by Country (2020-2031)
5.7.3 South America Recombinant Vector Vaccines Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Recombinant Vector Vaccines Market Facts & Figures by Country
5.8.1 Middle East and Africa Recombinant Vector Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Recombinant Vector Vaccines Sales by Country (2020-2031)
5.8.3 Middle East and Africa Recombinant Vector Vaccines Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Recombinant Vector Vaccines Sales by Type (2020-2031)
6.1.1 Global Recombinant Vector Vaccines Sales by Type (2020-2031) & (k units)
6.1.2 Global Recombinant Vector Vaccines Sales Market Share by Type (2020-2031)
6.2 Global Recombinant Vector Vaccines Revenue by Type (2020-2031)
6.2.1 Global Recombinant Vector Vaccines Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Recombinant Vector Vaccines Revenue Market Share by Type (2020-2031)
6.3 Global Recombinant Vector Vaccines Price by Type (2020-2031)
7 Segment by Application
7.1 Global Recombinant Vector Vaccines Sales by Application (2020-2031)
7.1.1 Global Recombinant Vector Vaccines Sales by Application (2020-2031) & (k units)
7.1.2 Global Recombinant Vector Vaccines Sales Market Share by Application (2020-2031)
7.2 Global Recombinant Vector Vaccines Revenue by Application (2020-2031)
7.2.1 Global Recombinant Vector Vaccines Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Recombinant Vector Vaccines Revenue Market Share by Application (2020-2031)
7.3 Global Recombinant Vector Vaccines Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Recombinant Vector Vaccines Value Chain Analysis
8.1.1 Recombinant Vector Vaccines Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Recombinant Vector Vaccines Production Mode & Process
8.2 Recombinant Vector Vaccines Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Recombinant Vector Vaccines Distributors
8.2.3 Recombinant Vector Vaccines Customers
9 Global Recombinant Vector Vaccines Analyzing Market Dynamics
9.1 Recombinant Vector Vaccines Industry Trends
9.2 Recombinant Vector Vaccines Industry Drivers
9.3 Recombinant Vector Vaccines Industry Opportunities and Challenges
9.4 Recombinant Vector Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Recombinant Vector Vaccines Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
Table 6. Global Recombinant Vector Vaccines Sales (k units) of Manufacturers (2020-2025)
Table 7. Global Recombinant Vector Vaccines Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Recombinant Vector Vaccines Revenue of Manufacturers (2020-2025)
Table 9. Global Recombinant Vector Vaccines Revenue Share by Manufacturers (2020-2025)
Table 10. Global Market Recombinant Vector Vaccines Average Price (US$/unit) of Manufacturers (2020-2025)
Table 11. Global Recombinant Vector Vaccines Industry Ranking, 2023 VS 2024 VS 2025
Table 12. Global Manufacturers of Recombinant Vector Vaccines, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Recombinant Vector Vaccines, Product Type & Application
Table 14. Global Recombinant Vector Vaccines Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Recombinant Vector Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. SANOFI PASTEUR S.A. Company Information
Table 19. SANOFI PASTEUR S.A. Business Overview
Table 20. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 21. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio
Table 22. SANOFI PASTEUR S.A. Recent Developments
Table 23. CNBG Company Information
Table 24. CNBG Business Overview
Table 25. CNBG Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 26. CNBG Recombinant Vector Vaccines Product Portfolio
Table 27. CNBG Recent Developments
Table 28. SINOVAC BIOTECH Company Information
Table 29. SINOVAC BIOTECH Business Overview
Table 30. SINOVAC BIOTECH Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 31. SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio
Table 32. SINOVAC BIOTECH Recent Developments
Table 33. Zhifei Company Information
Table 34. Zhifei Business Overview
Table 35. Zhifei Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 36. Zhifei Recombinant Vector Vaccines Product Portfolio
Table 37. Zhifei Recent Developments
Table 38. GSK Company Information
Table 39. GSK Business Overview
Table 40. GSK Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 41. GSK Recombinant Vector Vaccines Product Portfolio
Table 42. GSK Recent Developments
Table 43. Hualan Bio Company Information
Table 44. Hualan Bio Business Overview
Table 45. Hualan Bio Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 46. Hualan Bio Recombinant Vector Vaccines Product Portfolio
Table 47. Hualan Bio Recent Developments
Table 48. ChengDa Bio Company Information
Table 49. ChengDa Bio Business Overview
Table 50. ChengDa Bio Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 51. ChengDa Bio Recombinant Vector Vaccines Product Portfolio
Table 52. ChengDa Bio Recent Developments
Table 53. NuoCheng Bio Company Information
Table 54. NuoCheng Bio Business Overview
Table 55. NuoCheng Bio Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 56. NuoCheng Bio Recombinant Vector Vaccines Product Portfolio
Table 57. NuoCheng Bio Recent Developments
Table 58. Novartis Company Information
Table 59. Novartis Business Overview
Table 60. Novartis Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 61. Novartis Recombinant Vector Vaccines Product Portfolio
Table 62. Novartis Recent Developments
Table 63. Kangtai Company Information
Table 64. Kangtai Business Overview
Table 65. Kangtai Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 66. Kangtai Recombinant Vector Vaccines Product Portfolio
Table 67. Kangtai Recent Developments
Table 68. Changsheng Life Company Information
Table 69. Changsheng Life Business Overview
Table 70. Changsheng Life Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 71. Changsheng Life Recombinant Vector Vaccines Product Portfolio
Table 72. Changsheng Life Recent Developments
Table 73. Global Recombinant Vector Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 74. Global Recombinant Vector Vaccines Sales by Region (2020-2025) & (k units)
Table 75. Global Recombinant Vector Vaccines Sales Market Share by Region (2020-2025)
Table 76. Global Recombinant Vector Vaccines Sales by Region (2026-2031) & (k units)
Table 77. Global Recombinant Vector Vaccines Sales Market Share by Region (2026-2031)
Table 78. Global Recombinant Vector Vaccines Revenue by Region (2020-2025) & (US$ Million)
Table 79. Global Recombinant Vector Vaccines Revenue Market Share by Region (2020-2025)
Table 80. Global Recombinant Vector Vaccines Revenue by Region (2026-2031) & (US$ Million)
Table 81. Global Recombinant Vector Vaccines Revenue Market Share by Region (2026-2031)
Table 82. North America Recombinant Vector Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 83. North America Recombinant Vector Vaccines Sales by Country (2020-2025) & (k units)
Table 84. North America Recombinant Vector Vaccines Sales by Country (2026-2031) & (k units)
Table 85. North America Recombinant Vector Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 86. North America Recombinant Vector Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 87. Europe Recombinant Vector Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 88. Europe Recombinant Vector Vaccines Sales by Country (2020-2025) & (k units)
Table 89. Europe Recombinant Vector Vaccines Sales by Country (2026-2031) & (k units)
Table 90. Europe Recombinant Vector Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 91. Europe Recombinant Vector Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 92. Asia Pacific Recombinant Vector Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 93. Asia Pacific Recombinant Vector Vaccines Sales by Country (2020-2025) & (k units)
Table 94. Asia Pacific Recombinant Vector Vaccines Sales by Country (2026-2031) & (k units)
Table 95. Asia Pacific Recombinant Vector Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 96. Asia Pacific Recombinant Vector Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 97. South America Recombinant Vector Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 98. South America Recombinant Vector Vaccines Sales by Country (2020-2025) & (k units)
Table 99. South America Recombinant Vector Vaccines Sales by Country (2026-2031) & (k units)
Table 100. South America Recombinant Vector Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 101. South America Recombinant Vector Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 102. Middle East and Africa Recombinant Vector Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 103. Middle East and Africa Recombinant Vector Vaccines Sales by Country (2020-2025) & (k units)
Table 104. Middle East and Africa Recombinant Vector Vaccines Sales by Country (2026-2031) & (k units)
Table 105. Middle East and Africa Recombinant Vector Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 106. Middle East and Africa Recombinant Vector Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 107. Global Recombinant Vector Vaccines Sales by Type (2020-2025) & (k units)
Table 108. Global Recombinant Vector Vaccines Sales by Type (2026-2031) & (k units)
Table 109. Global Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Table 110. Global Recombinant Vector Vaccines Sales Market Share by Type (2026-2031)
Table 111. Global Recombinant Vector Vaccines Revenue by Type (2020-2025) & (US$ Million)
Table 112. Global Recombinant Vector Vaccines Revenue by Type (2026-2031) & (US$ Million)
Table 113. Global Recombinant Vector Vaccines Revenue Market Share by Type (2020-2025)
Table 114. Global Recombinant Vector Vaccines Revenue Market Share by Type (2026-2031)
Table 115. Global Recombinant Vector Vaccines Price by Type (2020-2025) & (US$/unit)
Table 116. Global Recombinant Vector Vaccines Price by Type (2026-2031) & (US$/unit)
Table 117. Global Recombinant Vector Vaccines Sales by Application (2020-2025) & (k units)
Table 118. Global Recombinant Vector Vaccines Sales by Application (2026-2031) & (k units)
Table 119. Global Recombinant Vector Vaccines Sales Market Share by Application (2020-2025)
Table 120. Global Recombinant Vector Vaccines Sales Market Share by Application (2026-2031)
Table 121. Global Recombinant Vector Vaccines Revenue by Application (2020-2025) & (US$ Million)
Table 122. Global Recombinant Vector Vaccines Revenue by Application (2026-2031) & (US$ Million)
Table 123. Global Recombinant Vector Vaccines Revenue Market Share by Application (2020-2025)
Table 124. Global Recombinant Vector Vaccines Revenue Market Share by Application (2026-2031)
Table 125. Global Recombinant Vector Vaccines Price by Application (2020-2025) & (US$/unit)
Table 126. Global Recombinant Vector Vaccines Price by Application (2026-2031) & (US$/unit)
Table 127. Key Raw Materials
Table 128. Raw Materials Key Suppliers
Table 129. Recombinant Vector Vaccines Distributors List
Table 130. Recombinant Vector Vaccines Customers List
Table 131. Recombinant Vector Vaccines Industry Trends
Table 132. Recombinant Vector Vaccines Industry Drivers
Table 133. Recombinant Vector Vaccines Industry Restraints
Table 134. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Recombinant Vector Vaccines Product Image
Figure 5. Global Recombinant Vector Vaccines Revenue (US$ Million), 2020 VS 2024 VS 2031
Figure 6. Global Recombinant Vector Vaccines Market Size (2020-2031) & (US$ Million)
Figure 7. Global Recombinant Vector Vaccines Sales (2020-2031) & (k units)
Figure 8. Global Recombinant Vector Vaccines Average Price (US$/unit) & (2020-2031)
Figure 9. Varicella Product Image
Figure 10. Influenza Product Image
Figure 11. Hepatitis Product Image
Figure 12. Pneumococcal Product Image
Figure 13. Pertussis, Diphtheria, tetanus Product Image
Figure 14. Others Product Image
Figure 15. For Adult Product Image
Figure 16. For Child Product Image
Figure 17. Global Recombinant Vector Vaccines Revenue Share by Manufacturers in 2024
Figure 18. Global Manufacturers of Recombinant Vector Vaccines, Manufacturing Sites & Headquarters
Figure 19. Global Top 5 and 10 Recombinant Vector Vaccines Players Market Share by Revenue in 2024
Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Recombinant Vector Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. Global Recombinant Vector Vaccines Sales by Region in 2024
Figure 23. Global Recombinant Vector Vaccines Revenue by Region in 2024
Figure 24. North America Recombinant Vector Vaccines Market Size by Country in 2024
Figure 25. North America Recombinant Vector Vaccines Sales Market Share by Country (2020-2031)
Figure 26. North America Recombinant Vector Vaccines Revenue Market Share by Country (2020-2031)
Figure 27. United States Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe Recombinant Vector Vaccines Market Size by Country in 2024
Figure 30. Europe Recombinant Vector Vaccines Sales Market Share by Country (2020-2031)
Figure 31. Europe Recombinant Vector Vaccines Revenue Market Share by Country (2020-2031)
Figure 32. Germany Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. France Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. U.K. Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Italy Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Netherlands Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Asia Pacific Recombinant Vector Vaccines Market Size by Country in 2024
Figure 38. Asia Pacific Recombinant Vector Vaccines Sales Market Share by Country (2020-2031)
Figure 39. Asia Pacific Recombinant Vector Vaccines Revenue Market Share by Country (2020-2031)
Figure 40. China Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Japan Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. South Korea Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. India Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Australia Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. China Taiwan Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Southeast Asia Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Southeast Asia Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. South America Recombinant Vector Vaccines Market Size by Country in 2024
Figure 49. South America Recombinant Vector Vaccines Sales Market Share by Country (2020-2031)
Figure 50. South America Recombinant Vector Vaccines Revenue Market Share by Country (2020-2031)
Figure 51. Mexico Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Brazil Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Argentina Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Middle East and Africa Recombinant Vector Vaccines Market Size by Country in 2024
Figure 55. Middle East and Africa Recombinant Vector Vaccines Sales Market Share by Country (2020-2031)
Figure 56. Middle East and Africa Recombinant Vector Vaccines Revenue Market Share by Country (2020-2031)
Figure 57. Turkey Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Saudi Arabia Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. UAE Recombinant Vector Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 60. Global Recombinant Vector Vaccines Sales Market Share by Type (2020-2031)
Figure 61. Global Recombinant Vector Vaccines Revenue Market Share by Type (2020-2031)
Figure 62. Global Recombinant Vector Vaccines Price (US$/unit) by Type (2020-2031)
Figure 63. Global Recombinant Vector Vaccines Sales Market Share by Application (2020-2031)
Figure 64. Global Recombinant Vector Vaccines Revenue Market Share by Application (2020-2031)
Figure 65. Global Recombinant Vector Vaccines Price (US$/unit) by Application (2020-2031)
Figure 66. Recombinant Vector Vaccines Value Chain
Figure 67. Recombinant Vector Vaccines Production Mode & Process
Figure 68. Direct Comparison with Distribution Share
Figure 69. Distributors Profiles
Figure 70. Recombinant Vector Vaccines Industry Opportunities and Challenges
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.